An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
← catalyst calendarNCT07459660 · readout ≤ 955 d
Sponsored by MapLight Therapeutics (industry) · MPLT — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
210estimated
Sites
8
Countries
Bulgaria, France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-25 | actual | When the study began enrolling |
| Primary completion | Mar 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Psychosis Associated With Alzheimer's Disease
Intervention
- Drug: ML-007C-MA
Primary outcome
what the primary-completion date above is the date OFTo assess the safety and tolerability of long-term ML-007C-MA administration in participants with hallucinations and delusions associated with AD
measured From initial dose through end of treatment (up to 52 weeks)
Permalink · MPLT's whole pipeline · Catalyst calendar · Every registered study · What changed